S1PR modulators linked to seizure risk in MS trial meta-analysis
People with multiple sclerosis (MS) have a twofold higher risk of seizures compared with the general population, according to pooled data from clinical trials. Among MS patients, treatment with sphingosine-1-phosphate receptor (S1PR) modulators, a class of MS disease-modifying therapies (DMTs) that includes the oral medications Gilenya (fingolimod),…